HOUSTON, July 29, 2020 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology, announced
today that it will report its second quarter 2020 financial results
and provide a business update on Tuesday,
August 11, 2020 before the open of the U.S. financial
markets.
Management will host a conference call and live webcast to
discuss Soliton's financial results at 8:30
a.m. ET that same day. A question and answer session will
follow management remarks.
The dial-in numbers for the conference call are (833) 423-0479
for domestic callers and (918) 922-2373 for international
callers. The conference ID is 4287640.
A replay of the call will be available following its completion
through August 18, 2020. To access
the replay, dial (855) 859-2056 for domestic callers and (404)
537-3406 for international callers and use the replay conference ID
4287640.
A live audio webcast of the call and an updated investor
presentation will be available on the Investor Relations page of
the Soliton, Inc. website, https://ir.soliton.com/. A replay
of the webcast will be archived on Soliton's website for 30 days
following the completion of the call.
------------------------
Join our more than 200K
subscribers here to follow the
Company: https://soly-investors.com
------------------------
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson
Cancer Center. The Company's first FDA cleared commercial product
will use rapid pulses of acoustic shockwaves as an accessory to
lasers for the removal of unwanted tattoos. The Company is based in
Houston, Texas, and is actively
engaged in bringing the Rapid Acoustic Pulse ("RAP") device to the
market. The Company believes this "Soliton" method has the
potential to lower tattoo removal costs for patients, while
increasing profitability to practitioners, compared to current
laser removal methods. Soliton is investigating potential
additional capabilities of the RAP technology in clinical and
preclinical testing, including the potential to improve the
appearance of cellulite and the potential to treat keloid and
hypertrophic scars by targeting the stiffened environment in the
intracellular matrix. The RAP device has received 510(k)
clearance for use in tattoo removal but remains investigational for
use in improving the appearance of cellulite and scar
treatment.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. These statements relate to future events,
future expectations, plans and prospects. Although Soliton believes
that the expectations reflected in such forward-looking statements
are reasonable as of the date made, expectations may prove to have
been materially different from the results expressed or implied by
such forward-looking statements. Soliton has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under in our SEC filings,
including under the heading "Item 1A. Risk Factors" in the Form
10-K for year ended December 31, 2019
we filed with the SEC on March 2,
2020 and updated from time to time in our Form 10-Q filings
and in our other public filings with the SEC. Any
forward-looking statements contained in this release speak only as
of its date. Soliton undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-announces-second-quarter-2020-financial-results-and-business-update-on-tuesday-august-11-2020-301101923.html
SOURCE Soliton, Inc.